Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Newbie + cycloserine Maria3667

Posted by SLS on May 20, 2008, at 13:15:35

In reply to Re: Newbie + cycloserine SLS, posted by Maria3667 on May 20, 2008, at 12:59:55

Here's one I found. There is very little, if any, study of cycloserine in depression. It is used for an adjunct to treatment of the negative symptoms of schizophrenia.


1: J Affect Disord. 2006 Jul;93(1-3):239-43. Epub 2006 May 4.Click here to read Links
Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, Kremer I.

Ezrath Nashim-Herzog Memorial Hospital and Department of Psychiatry, Hadassah Medical School, Hebrew University, Jerusalem, Israel.

BACKGROUND: Compounds that reduce N-methyl-d-aspartate receptor (NMDAR) function, including NMDAR antagonists and partial agonists at the NMDAR-associated glycine (GLY) site, may act as antidepressants. The antibiotic drug d-cycloserine (DCS) acts as a partial agonist at the NMDAR-GLY site. Preclinical and clinical data suggest that at dosages >or=100 mg/day DCS acts as a functional NMDAR antagonist and may have antidepressant effects. METHODS: Twenty-two treatment resistant major depression patients participated in a double-blind, placebo-controlled 6-week crossover trial with 250 mg/day DCS added to their ongoing antidepressant medications. RESULTS: DCS treatment was well tolerated and resulted in symptom reductions. However, biweekly-performed clinical assessments, including the Hamilton Depression Rating Scale, Hamilton Rating Scale for Anxiety and Zung Self-Rating Depression Scale did not reveal statistically significant therapeutic advantages of DCS vs. placebo adjuvant treatment. LIMITATIONS: Small sample, uneven treatment resistance criteria across subjects. The exposure to DCS (dose/length of treatment) may not have been sufficient. CONCLUSIONS: This exploratory study represents the first attempt to assess the effects of a NMDAR-GLY site partial agonist in depression treatment. The findings and limitations of this study should be taken into account in the planning of future clinical trials with NMDAR modulators in depression.

PMID: 16677714 [PubMed - indexed for MEDLINE]




Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.


Start a new thread

Google www
Search options and examples
[amazon] for

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:SLS thread:830088